NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company and subsidiary of SciSparc Ltd., has achieved a critical regulatory milestone in its FDA-approved clinical trial program for SCI-110, a proprietary cannabinoid-based drug candidate for Tourette Syndrome (TS) in adults. The company announced it has successfully completed manufacturing of the investigational product and secured the required batch release certification from a European Qualified Person (QP). This certification is a mandatory regulatory step that authorizes the shipment of clinical trial material to participating study sites, a prerequisite for site activation and patient enrollment.
The Phase IIb trial is being conducted at three leading clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All sites have completed their initiation activities and are prepared to receive drug supplies following the QP release. The completion of site initiation across all centers, combined with the European QP release, represents a significant operational milestone for NeuroThera, as it now advances toward patient enrollment with investigational product shipments expected in the near term.
SCI-110 combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form and is patent-protected. The Phase IIb study is designed to evaluate the efficacy, safety, and tolerability of SCI-110 in adults with TS, a condition that presents substantial unmet treatment needs. The progression to patient enrollment is a pivotal step in the clinical development pathway, as it marks the transition from preparatory activities to the actual generation of clinical data that will inform future regulatory submissions and potential commercialization.
The announcement, reported via NEWMEDIAWIRE, underscores NeuroThera's operational execution and its ability to navigate complex international regulatory requirements. The involvement of three prestigious institutions across three countries highlights the global interest in developing new therapies for TS and the company's commitment to conducting a robust, multicenter trial. For investors and stakeholders, the QP release reduces near-term execution risk and signals that the trial is on track to begin enrolling patients, a key value inflection point for clinical-stage biotech companies.
As a subsidiary of SciSparc Ltd., NeuroThera benefits from shared expertise and resources in developing novel therapeutics for central nervous system disorders. The company's focus on innovative drug combinations addresses underserved health conditions, and the progress of SCI-110 could potentially offer a new treatment option for TS patients who currently have limited therapeutic choices. Further details about the company's disclosures are available on SEDAR+ at www.sedarplus.ca.
